TScan Therapeutics’ (TCRX) Overweight Rating Reiterated at Morgan Stanley

Morgan Stanley reiterated their overweight rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report released on Friday,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other equities research analysts also recently weighed in on TCRX. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Needham & Company LLC lowered their target price on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 6th. Finally, Barclays lowered their price objective on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.33.

TScan Therapeutics Price Performance

Shares of TCRX opened at $1.74 on Friday. TScan Therapeutics has a 52 week low of $1.71 and a 52 week high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $98.47 million, a price-to-earnings ratio of -1.64 and a beta of 0.91. The stock has a 50 day moving average of $2.28 and a 200-day moving average of $3.85.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. As a group, analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Trading of TScan Therapeutics

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new position in TScan Therapeutics during the 4th quarter worth $32,000. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics during the fourth quarter valued at about $32,000. ProShare Advisors LLC acquired a new stake in TScan Therapeutics in the fourth quarter worth about $40,000. Wells Fargo & Company MN grew its position in TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after buying an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in TScan Therapeutics in the 4th quarter valued at about $59,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.